The High Mobility Group proteins HMGA1 are nuclear architectural factors that play a critical role in a wide range of biological processes. Since recent studies have identified the microRNAs (miRNAs) as important regulators of gene expression, modulating critical cellular functions such as proliferation, apoptosis and differentiation, the aim of our work was to identify the miRNAs that are physiologically regulated by HMGA1 proteins. To this purpose, we have analysed the miRNA expression profile of mouse embryonic fibroblasts (MEFs) carrying two, one or no Hmga1 functional alleles using a microarray (miRNA microarray). By this approach, we found a miRNA expression profile that differentiates Hmga1-null MEFs from the wild-type ones. In particular, a significant decrease in miR-196a-2, miR-101b, miR-331 and miR-29a was detected in homozygous Hmga1-knockout MEFs in comparison with wild-type cells. Consistently, these miRNAs are downregulated in most of the analysed tissues of Hmga1-null mice in comparison with the wild-type mice. ChIP assay shows that HMGA1 is able to bind regions upstream of these miRNAs. Moreover, we identified the HMGA2 gene product as a putative target of miR-196a-2, suggesting that HMGA1 proteins are able to downregulate the expression of the other member of the HMGA family through the regulation of the miR-196a-2 expression. Finally, ATXN1 and STC1 gene products have been identified as targets of miR-101b. Therefore, it is reasonable to hypothesize that HMGA1 proteins are involved in several functions by regulating miRNA expression.
Introduction
The High Mobility Group A (HMGA) protein family includes HMGA1a and HMGA1b, which are encoded by the HMGA1 gene through an alternative splicing (Johnson et al., 1989) , and the closely related HMGA2 protein, which is encoded by a different gene (Manfioletti et al., 1991) . These proteins bind the minor groove of AT-rich DNA sequences through three short basic repeats, called 'AT-hooks', located at the NH2-terminal region of the proteins. The mammalian HMGA proteins play key roles in chromatin architecture and gene control by serving as generalized chromatin effectors, either enhancing or suppressing the ability of most usual transcriptional activators and repressors to act within the confines of chromatinized DNA (Reeves and Nissen, 1990; Thanos and Maniatis, 1995) .
Both HMGA genes are widely expressed during embryogenesis, whereas their expression is low or absent in most of the normal adult tissues Chiappetta et al., 1996) . Conversely, their expression again becomes abundant in most human malignant neoplasias (Tallini and Dal Cin, 1999) . Several studies indicate that HMGA gene overexpression plays a critical role in the process of carcinogenesis and their oncogenic activity has been demonstrated in vitro and in vivo (Fusco and Fedele, 2007) . In fact, either HMGA1 or HMGA2 overexpression is able to transform mouse and rat fibroblasts (Fedele et al., 1998; Scala et al., 2000) , and transgenic mice overexpressing either HMGA1 or HMGA2 develop natural killer-T lymphomas and pituitary adenomas (Baldassarre et al., 2001; Fedele et al., 2002 Fedele et al., , 2005 . Interestingly, the HMGA1 gene also seems to have a tumor suppressor role in oncogenesis since the Hmga1-null mice, even at the heterozygous state, develop B-cell lymphomas and myeloid malignancies, other than cardiac hypertrophy and type II diabetes (Foti et al., 2005; Fedele et al., 2006) .
In a previous work, we searched for genes regulated by HMGA1 proteins, using microarray analysis in embryonic stem cells bearing one or two disrupted Hmga1 alleles. We identified that 87 transcripts increased and 163 transcripts decreased by at least four-fold in Hmga1 À/À embryonic stem cells. For some of them, a Hmga1-dose dependency was observed. For a couple of analysed HMGA1-regulated genes, electrophoretic mobility shift assay and chromatin immunoprecipitation (ChIP) revealed a direct binding of HMGA1 proteins to their promoters, suggesting an HMGA1-direct regulation of their expression (Martinez Hoyos et al., 2004) .
MicroRNAs (miRNAs) are a class of genes encoding short RNAs, which control gene expression by inhibiting translation or inducing cleavage of target mRNAs. miRNAs are aberrantly expressed in cancer tissues, and links between deregulated miRNAs and the molecular pathways involved in carcinogenesis have been established (Negrini et al., 2007) . Several studies have shown that miRNAs play important roles in essential processes such as differentiation, cell growth and cell death (Miska, 2005; Zamore and Haley, 2005) . Recent evidences indicate that miRNAs could contribute to oncogenesis, participating as tumor suppressors or as oncogenes (Kent and Mendell, 2006) . In fact, miR-21 was shown to directly target the tumor suppressor PTEN (encoding a phosphatase that can inhibit growth and/or survival pathways) in cholangiocarcinoma cells (Meng et al., 2007) . Moreover, the miR-221/222 cluster, upregulated in thyroid and prostate cancer, was shown to target the p27 kip1 protein, a critical negative regulator of the cell cycle (Galardi et al., 2007; Visone et al., 2007) . Therefore, it is reasonable to hypothesize that HMGA1 proteins are involved in several functions regulating the miRNA expression.
In the present work, we have carried out miRNA expression profiling of mouse embryonic fibroblasts (MEFs) isolated from Hmga1-knockout and wild-type mice to identify the miRNAs regulated by the HMGA1 proteins. Among the miRNAs differentially expressed in wild-type and Hmga1-null MEFs, we focused our attention on a subset of miRNAs, including the miR196a-2 and miR-101b, downregulated in homozygous Hmga1-knockout MEFs with respect to the wild-type ones. Finally, we identified the HMGA2 gene product as a target of miR-196a-2 and the ATXN1 and STC1 gene products as targets of miR-101b.
Results
miRNA expression profile of embryonic fibroblasts isolated from Hmga1-knockout mice We used a miRNA microarray to evaluate the miRNA expression profile of MEFs deriving from Hmga1-knockout mice. The wild-type MEFs were matched with those bearing one or two disrupted Hmga1 alleles. Applying the analysis of variance, we obtained a list of differentially expressed miRNAs (Po0.05) between wild-type and homozygous mutants (Table 1) . Six miRNAs (miR-196a-2, miR101b, miR-331, miR-29a, miR-346 and miR-130b) were overexpressed with a fold-change equal or higher than two in the wild-type samples versus homozygous mutants. In contrast, none of the analysed miRNAs showed more than two-fold reduction in its expression in the wild-type compared to Hmga1 Figure 1 ). Interestingly, for miR-196a-2 and miR-101b, the differences in their expression between wild-type and Hmga1-null MEFs were even higher than those shown by the microarray analysis. Then, we decided to concentrate on the miR-101b and miR-196a-2, which showed the highest fold-change decrease in Hmga1-null MEFs (Table 1) .
Subsequently, we analysed miR-196a-2 and miR-101b expressions by real-time RT-PCR on different tissues from Hmga1 þ / þ , Hmga1 þ /À and Hmga1 À/À mice. As shown in the Figure 2a , miR-101b was downregulated, as described for MEFs, in the spleen, heart, thymus and brain of heterozygous and homozygous Hmga1-null mice with respect to the wild-type tissues, whereas no differences in its expression were observed in the liver, and its expression was not detected in the lung. The expression trend of miR-196a-2 in the liver, heart, lung and brain was similar to that observed in Hmga1 þ / þ with respect to Hmga1 À/À MEFs, being significantly downregulated in heterozygous and homozygous Hmga1-null mice. Conversely, no differences in miR196a-2 expression were observed in the spleen, and no expression at all was observed in the thymus (Figure 2b) . In some cases, such as miR-196a-2 in the liver ( Figure 2b ) and miR-101b in the spleen (Figure 2a) , the reduction of their expression was HMGA1-dosedependent. These results are consistent with our previous ones showing that the gene expression regulation by the HMGA1 proteins is dependent on the cellular context (Martinez Hoyos et al., 2004) .
HMGA1 proteins directly bind the miR-101b and miR-196a-2 upstream regions To verify that HMGA1 proteins are able to bind to the miR-101b or miR-196a-2 upstream regions in vivo, we performed ChIP experiments in Hmga1
and Hmga1 À/À MEFs. Chromatin prepared as described under Materials and methods was immunoprecipitated with anti-HMGA1 or rabbit IgG antibodies, used as internal control. In particular, we analysed a region of qRT-PCR analysis of miR-101b, miR-196a-2, miR-331 and miR29a precursors was carried out on MEFs obtained from wild-type (MEFs þ / þ ), heterozygous (MEFs þ /À ) and homozygous (MEFs À/À ) mice for the Hmga1-null mutation. The fold-change values indicate the relative change in the expression levels between homozygous and heterozygous samples and the wild-type sample, assuming that the value of the wild-type sample was equal to 1. Each bar represents the mean value±s.e. from three independent experiments performed in triplicates *Po0.05, **Po0.01 vs
Figure 2 Expression of miR-196a-2 and miR-101b in Hmga1-knockout mouse tissues. qRT-PCR analysis of (a) miR-101b and (b) miR-196a-2 precursors was carried out on the spleen, liver, heart, thymus, lung and brain deriving from Hmga1 þ / þ , Hmga1 þ /À and Hmga1 À/À mice. Each bar represents the mean value ± s.e. from three different mice. *Po0.05, **Po0.01 vs wild-type control.
HMGA1 regulate microRNA expression I De Martino et al 2,000 bp upstream of the precursor sequence of miR101b and miR-196a-2 to search for AT-rich putative HMGA1-binding sites. The results shown in Figure 3 demonstrate that HMGA1 proteins bind to these sequences. In fact, the miR-101b and miR-196a-2 upstream regions were amplified from the DNA recovered with anti-HMGA1 antibody in wild-type and Hmga1
, but not in Hmga1 À/À MEFs. Moreover, no amplification was observed in samples immunoprecipitated with rabbit IgG.
ATXN1 and STC1 are targets of miR-101b
To search for potential mRNA targets of the HMGA1-regulated miRNAs, we used the miRGen program (http://www.diana.pcbi.upenn.edu/miRGen.html) as a bioinformatic tool. Among the several genes predicted as potential targets of the miR-101b, we selected ATXN1 and STC1 because of their biological function in development and cancer. The gene ATXN1, which is mutated to contain an expanded CAG trinucleotide repeat in spinocerebellar ataxia-1, encodes for the protein Ataxin 1. Ataxin 1 is detected in various brain regions and in non-neuronal tissues, such as the heart, skeletal muscle and liver (Servadio et al., 1995; Tsai et al., 2004) . Stanniocalcin1, encoded by STC1 gene, is a glycoprotein hormone and it has a role in many physiological processes, including bone development, reproduction, wound healing, angiogenesis and modulation of inflammatory response (Ishibashi and Imai, 2002; Chang et al., 2003) . The STC1 gene is expressed in a wide variety of tissues, including the kidney, prostate, thyroid, bone and ovary (Chang et al., 1995; Olsen et al., 1996; Varghese et al., 1998) . Recently, STC1 overexpression has been found in hepatocellular, colorectal, breast and medullary thyroid carcinomas (Fujiwara et al., 2000; Okabe et al., 2001; Watanabe et al., 2002; McCudden et al., 2004) .
Three sites in the 3 0 -UTR of ATXN1 gene and three in the 3 0 -UTR of STC1 gene, that match the miR-101b 'seed sequence', were predicted ( Figure 4a ). To validate the influence of miR-101b on the selected candidate targets, we transfected the miR-101b or its inhibitor, 2 0 -O-Me-101b, into the NIH3T3 cells, and searched for changes in ATXN1 and STC1 protein levels by western blot analysis. Introduction of miR-101b decreased the protein levels significantly (Figures 4b  and c) . Conversely, the inhibitor, 2 0 -O-Me-101b, does not change STC1 and ATXN1 protein amounts significantly.
Interestingly, no significant changes in the ATXN1 or STC1 mRNA levels were observed in the cells transfected with the miR-101b or its inhibitor (Figure 4d ). This result indicates a role of miR-101b in STC1 and ATXN1 post-transcriptional regulation, and excludes that miR-101b may affect ATXN1 or STC1 mRNA degradation.
Most miRNAs are thought to control gene expression by base pairing with the miRNA-recognizing elements (miR-RE) found in their messenger target. To demonstrate that the direct interaction between the miR-101b and STC1 or ATXN1 mRNA was responsible for decreased expression of these proteins, we inserted downstream of the luciferase ORF the 1310 bp (3390-4680) of the 3 0 -UTR of the ATXN1 mRNA, or the 988 bp (1029-1995) of the 3 0 -UTR of the STC1 mRNA, respectively. These reporter vectors were transfected into NIH3T3 cells with (a) the miR-101b oligonucleotide precursor, (b) the 2 0 -O-Me-101b and (c) a control not targeting scrambled oligonucleotide. The luciferase activity was markedly diminished after miR-101b transfection, as compared with the scrambled oligonucleotide (Po0.05). Conversely, an increase in the luciferase activity was observed after transfection with the miR-101b inhibitor (Po0.01 for STC1 and Po0.05 for ATXN1) (Figure 5a ). These results indicate that this miR interferes with ATXN1 and STC1 translation through direct interaction with their respective 3 0 -UTRs. This conclusion is further supported by similar experiments in which we used as reporter construct the same vector of the previous experiments, but carrying target sites modified by introducing point deletion in one, two or three sites together (Figure 5b ). For both target genes, only the reporter vector carrying deletion in all target sites was insensitive to the effect of miR-101b (Po0.01) (Figures 5c and d) , proving that the modification in only one or two target sites of the 3 0 -UTR is not sufficient to block the inhibitory function of this miR.
miR-196a-2 downregulates HMGA2
Using the same bioinformatic tool, we also searched for potential mRNA targets of mouse miR-196a-2. This analysis identified several candidate genes, but we put our attention on Hmga2 (Figure 6a ), another member of HMGA family, which maps on chromosome 12q13-15 and is causally involved in a variety of benign and malignant tumors Schoenmakers et al., 1995; Fedele et al., 2001; Fusco and Fedele, 2007) . To better investigate the influence of miR-196a-2 on Hmga2 expression, we searched for changes in HMGA2 protein and mRNA levels in NIH3T3 cells transfected with the miR-196a-2 precursor (miR-196a-2) or its No significant changes in the HMGA2 mRNA levels were observed in the cells transfected with the miR196a-2 or its inhibitors (Figure 6d ). The inverse pattern of expression of Hmga2 and miR-196a-2 suggested an in vivo interaction that we further investigated by luciferase assays. In fact, to show a direct interaction between the 3 0 -UTR of Hmga2 and miR-196a-2, we inserted the 3 0 -UTR region predicted to interact with this miR into a luciferase vector. Then, we tested the activity of the miR-196a-2 by cotransfecting the luciferase reporter vector bearing the 3 0 -UTR of Hmga2 with (a) the miR-196a-2 oligonucleotide precursors, (b) the 2 0 -O-Me196a-2 and (c) a control not targeting scrambled oligonucleotide. Consistent with the above data, indicating HMGA2 as a target of miR-196a-2, the relative luciferase activity was markedly diminished in cells transfected with miR-196a-2 compared to those transfected with the scrambled oligonucleotide (Po0.05). Conversely, a significant increase in the luciferase activity was observed after transfection with the miR196a-2 inhibitor (Figure 7a ).
To show that the effect of miR-196a-2 on the luciferase gene is dependent on the presence of the miR-196a-2-binding sites, we generated a panel of reporter constructs containing the HMGA2 3 0 -UTR, with the miR-196a-2-binding sites mutated individually or in combination (Figure 7b ). Although the mutation of one site did not influence the inhibitory effect of miR196a-2 on reporter gene expression, mutation of two sites together reduced the inhibitory effect to three-fold (Po0.01), suggesting that these two sites function cooperatively in mediating the inhibition of HMGA2 protein synthesis (Figure 7c ).
Discussion
The aim of this study was to identify miRNAs that are physiologically regulated by the HMGA1 proteins. To this purpose, we analysed, using a miRNA microarray platform, the miRNA expression profile of the MEFs carrying two, one or no Hmga1 functional alleles. We identified four miRNAs significantly downregulated in homozygous Hmga1-null MEFs with respect to the wild-type samples. Their expression, in particular that of miR-101b and miR-196a-2, is regulated by HMGA1 in a dose-dependent manner, with an intermediate expression level in MEFs carrying only one Hmga1 functional allele. Interestingly, none of the miRNAs analysed showed a significant increase in the MEFs null for Hmga1. This result would suggest that, at least in MEFs, the HMGA1 proteins positively regulate a limited number of miRNAs, whereas they do not seem to have a significant negative role in miRNA transcription. We focused our studies on miR-101b and miR-196a-2, which showed the highest fold-change. This regulation by HMGA1 was also confirmed in other mouse tissues, but not in all those analysed, confirming that the regulation of gene expression by the HMGA1 proteins is dependent on the cellular context. ChIP analysis confirmed that HMGA1 was able to bind to the upstream region of both these miRNAs, suggesting a direct control of the miR-101b and miR-196a-2 expressions by HMGA1.
We looked for possible targets of these miRNAs using appropriate bioinformatic programs. As far as the miR101b is concerned, two potential targets were identified: the Ataxin1 (ATXN1) and Stanniocalcin1 (STC1) proteins. Overexpression of miR-101b in NIH3T3 cells leads to a reduction of both these proteins, and to a reduced luciferase activity of ATXN1, or STC1 gene 3 0 -UTR-based reporter constructs. ATXN1 is an RNAbinding protein thought to act as a transcriptional repressor (Yue et al, 2001; Irwin et al., 2005) . The expression of pathogenic ATXN1 protein carrying expanded tracts of polyQ results in Spinocerebellar Ataxia type 1 (SCA1), a disease that decimates cerebellar Purkinje cells and brain stem neurons (Skinner et al., 1997) . Therefore, it is likely that HMGA1 might have a certain role in the development of the cerebellum, even though Hmga1-null mice do not show a gross impairment of the cerebellar functions. Moreover, since HMGA1 is overexpressed in most neuroblastoma tumors (Giannini et al., 1999 (Giannini et al., , 2000 , it is reasonable to hypothesize that the HMGA1 protein might contribute to the growth of the neuron stem cells, and to their transformation by modulating the ATXN1 expression. Studies are in progress to evaluate ATXN1 protein levels in neuroblastomas. While this manuscript was under submission for publication, a paper showing that the ATXN1 is a target of miR-101b was being published. The authors show that the miR-101b, together with miR-19 and miR-130, cooperatively regulate ATXN1 levels and their inhibition enhanced the cytotoxicity of polyglutamine-expanded ATXN1 in human cells (Lee et al., 2008) . They confirm that miRNAmediated post-transcriptional regulation of ATXN1 modulates SCA1 neuropathology by affecting the amount of the protein expressed. These data seem completely consistent with the data reported in this paper.
Another target of the miR-101b is the STC1 gene. It codes for a homodimeric glycoprotein hormone (Wagner et al., 1986) . The modulation of its expression has been revealed in numerous developmental, physiological and pathological processes. Recently, STC1 has also been reported to be induced in a variety of tumors including the breast (McCudden et al., 2004) , colon (Gerritsen et al., 2002) , ovary (Ismail et al., 2000) , lung cancer (Garber et al., 2001) , thyroid medullary carcinoma (Watanabe et al., 2002) , hepatocarcinoma (Okabe et al., 2001) , pheochromocytoma (Eisenhofer et al., 2004) , neuroblastoma (Wong et al., 2002) , osteosarcoma and fibrosarcoma (Jellinek et al., 2000) . The possible use of STC1 expression levels for the diagnosis of human breast, hepatocellular and colorectal cancer has also been proposed (Fujiwara et al., 2000; Wascher et al., 2003) . Moreover, it has been shown that the inherited mutations of the RET gene, responsible for the MEN2A and MEN2B, are able to induce STC1 expression (Watanabe et al., 2002) . Recently, a critical role of STC1 expression in the formation of tumor vasculature has been proposed. Indeed, it has been shown that STC1 expression is markedly increased in hypoxia, common phenomenon that occurs in region of most solid human tumor in the latter stage of carcinogenesis (Gerritsen , 2002) . STC1 expression would be induced by Hypoxia-inducible factor 1a (Yeung et al., 2005) and by vascular endothelial growth factor (Holmes and Zachary, 2008 ). Therefore, its increased level by miR-101b downregulation after HMGA1 induction might have an important role in the progression step of carcinogenesis in several human neoplasias all featured by HMGA1 overexpression. More recently STC1 has been proposed as a putative proapoptotic factor in the regulation of programmed cell death induced by p53 (Lai et al., 2007) . As far as the miR-196a-2 is concerned, we have identified as target the HMGA2 protein, the other member of the HMGA family.
This protein is implicated, through different mechanisms, in both benign and malignant neoplasias. Rearrangements of HMGA genes are a feature of most benign human mesenchymal tumors. Conversely, unrearranged HMGA overexpression is a feature of malignant tumors and is also causally related to neoplastic cell transformation. In fact, the block of the HMGA2 protein synthesis prevents thyroid cell transformation by acute murine retroviruses (Berlingieri et al., 1995) . Very recently, it has been shown that HMGA2 promotes neural stem cell self-renewal in young mice reducing p16 and p19 (Nishino et al., 2008) . Then, it is reasonable to hypothesize that the downregulation of miR-196a-2 leading to increased HMGA2 levels could represent a further mechanism by which HMGA1 overexpression can contribute to cell transformation. Also the HMGA2 gene has been found overexpressed in a large variety of experimental and human malignant neoplasias (Fusco and Fedele, 2007) . The identification of HMGA2 as a target of miR-196a-2 might also have some interesting implications in adipocytic cell growth and differentiation, in which HMGA1 and HMGA2 seem to have opposite functions (Battista et al., 1999; Melillo et al., 2001) . Consistent with the results reported here, we have recently found that the HMGA2 expression is increased in the Hmga1-null MEFs (De Martino, unpublished data) . Moreover, miR-196a-2 would represent the third miRNA able to target the HMGA2 mRNA. In fact, it has been previously shown that let-7 (Lee and Dutta, 2007) and miR-98 (Hebert et al., 2007) negatively regulate HMGA2 expression.
In conclusion, here we report that HMGA1 proteins are able to positively regulate the expression of miR101b and miR-196a-2 that have ATXN1 and STC1, and HMGA2 as genes target, respectively. This could represent another mechanism by which HMGA1 proteins play a role in the processes of differentiation and carcinogenesis.
Materials and methods

Cell lines and transfections
MEFs have been established from wild-type, Hmga1 þ /À and Hmga1 À/À embryos 12.5 days post coitum following standard procedures. Cells were grown in Dulbecco 0 s modified Eagle's medium (DMEM) supplemented with 10% FCS (fetal calf serum), glutamine and non-essential amino acids (Life Technologies Inc., Rockville, MD, USA) in a 5% CO 2 atmosphere. NIH3T3 were cultured at 37 1C (5% CO 2 ) in DMEM containing 10% FBS (fetal bovine serum) supplemented with penicillin and streptomycin in a humidified atmosphere of 95% air and 5% CO 2 .
For transfection assay, NIH3T3 cells were plated at a density of 2.5 Â 10 5 cells/well, in six-well plates, with three replicate wells for each condition, and transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. 2 0 -O-Me-101b (CUUC AGCUAUCACAGUACUGUAL) and 2 0 -O-Me-196a-2 (CC AACAACAUGAAACUACCUAL) oligonucleotides were used in the antisense experiments. All 2 0 -O-methyl oligonucleotides were synthesized by Fidelity Systems, Inc. (Gaithersburg, MD, USA) as described previously (Meister et al., 2004) and were used at 200 nM concentration. RNA oligonucleotides corresponding to pre-miR negative control (no. AM17110, Ambion, Austin, TX, USA), pre-miR-101b (AM12364) and pre-miR-196a-2AM10068) were used at 100 nM final concentration in the sense experiments.
RNA extraction and quantitative reverse transcription-PCR Total RNA isolation from mouse tissues and cells was carried out with Trizol (Invitrogen) according to the manufacturer's instructions. The integrity of the RNA was assessed by denaturing agarose gel electrophoresis (virtual presence of sharp 28S and 18S bands). Spectrophotometry qRT-PCRs analysis were carried out on the RNA isolated from tissues and MEFs of Hmga1-knockout mice and from transfected cells by using AmpliTaq DNA polymerase (Applied Biosystems, Foster City, CA, USA) and the mirVana qRT-PCR miRNA Detection Kit (Ambion) following the manufacturer's instructions. Reactions contained mirVana qRT-PCR Primer Sets (Ambion), specific for miR-101b, miR-196a-2 and GAPDH (used to normalize RNA levels). A qRT-PCR analysis for ATXN1, STC1 and HMGA2 mRNA was carried out by using TaqMan Gene Expression Assay (Ambion).
miRNA microarray
Microarray experimental procedures were performed as described earlier . Briefly, labeled targets from 5 mg of total RNA from each sample were biotin-labeled during reverse transcription using random hexamers. Hybridization was carried out on miRNA microarray (KCI version 1.0; ) containing 368 probes in triplicate, corresponding to 245 human and mouse miRNA genes. Hybridization signals were detected by biotin binding of a Streptavidin-Alexa 647 conjugate using a Perkin-Elmer ScanArray XL5K (Perkin-Elmer, Wellesley, MA, USA). Scanner images were quantified by the Quantarray software. Raw data were normalized and analysed in GENESPRING software, version 7.2 (Silicon Genetics, Redwood City, CA, USA). Expression data were median-centered by using the GENE-SPRING normalization option.
Quantitative RT-PCR for miRNA precursors Quantitative real-time PCR was performed as described by (Schmittgen et al., 2004) . Briefly, RNA was reverse transcribed to cDNA with gene-specific primers and Thermoscript (Invitrogen), and the relative amount of each miRNA was normalized to the GAPDH RNA using the equation 2 ÀDCT , where DC T ¼ (C T miRNA ÀC T GAPDH RNA ). PCR reactions were carried out in triplicate using iCycler (Bio-Rad, Hercules, CA, USA) with SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) as follows: 95 1C for 10 min and 
Plasmids and constructs
The 3 0 -UTR region of STC1 and ATXN1 genes including binding sites for miR-101b, and the 3 0 -UTR region of HMGA2 gene including binding sites for miR-196a-2, were amplified by PCR from genomic DNA by using the primers described in Supplementary Table 1 .
The amplified fragments were cloned into pGL 3 -Control firefly luciferase vector (Promega, Madison, WI, USA) at the XbaI site immediately downstream from the stop codon of luciferase.
Deletions into the miR-101b-binding sites of the ATXN1 gene or STC1 gene, 3 0 -UTR or into the miR-196a-2-binding sites of the Hmga2 gene, 3 0 -UTR were introduced by using QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) following the manufacturer's instructions. The primers used are listed in Supplementary Table 1 .
Transfection efficiency was corrected by transfection of Renilla luciferase vector (pRL-CMV, Promega).
Luciferase target assays NIH3T3 cells were co-transfected in 12-well plates with the modified firefly luciferase vector described above, the Renilla luciferase reporter plasmid and with the RNA oligonucleotides. Firefly and Renilla luciferase activities were measured 24 h after transfection with the Dual-Luciferase Reporter Assay System (Promega). Firefly activity was normalized to Renilla activity as control of the transfection efficiency.
Protein extraction, western blotting, and antibodies Tissues and cells were lysed in lysis buffer containing 1% NP-40, 1 mM EDTA, 50 mM Tris-HCl (pH 7.5) and 150 mM NaCl, supplemented with complete protease inhibitors mixture (Roche Diagnostic Corp., Indianapolis, IN, USA). Total proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Bio-Rad). Membranes were blocked with 5% nonfat milk and incubated with antibodies against STC1 (sc-14346, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), ATXN1 (sc-8766, Santa Cruz Biotechnology Inc.), HMGA2
(polyclonal rabbit antibody raised against a synthetic peptide located in the NH2-terminal region), vinculin (sc-7649, Santa Cruz Biotechnology Inc.). Bound antibody was detected by the appropriate secondary antibody and revealed with an enhanced chemiluminescence system (Amersham-Pharmacia Biotech, Piscataway, NJ, USA). The level of expression of different proteins was analysed by using the public domain software Image J (a Java image processing program inspired by National Institutes of Health (NIH) Image for Macintosh) by working in a linear range. It can calculate area and pixel value statistics of user-defined selections. Briefly, it was done as follows: X-ray films were scanned and saved as eight-bit grayscale JPEG files. The percentage of measurable pixels in the image was set (and highlighted in red) by using the adjust image threshold command. The number of square pixels in the section selected (the protein bands) was then counted by measuring the area in the binary or threshold image.
ChIP
Approximately 3 Â 10 7 Hmga1 þ / þ , Hmga1 þ /À and Hmga1
À/À
MEFs were grown on 75 cm 2 dishes. ChIP was carried out with a ChIP assay kit (Upstate Biotechnology, Lake Placid, NY, USA) according to the manufacturer's instruction. PCR reactions were performed with AmpliTaq gold DNA polymerase (Perkin-Elmer). The recovered DNA was PCR-amplified with the primers described in Supplementary Table 1 .
Statistical analysis
For the comparison between two groups of experiments, Student's t-test was used. The statistical significant difference was considered when P-value was less than 0.05. miRNA microarray data were compared with the GENESPRING ANOVA tool.
